Benserazide is a novel inhibitor targeting PKM2 for melanoma treatment
Benserazide is a novel inhibitor targeting PKM2 for melanoma treatment
复制标题
苄丝肼是一种靶向 PKM2 的新型抑制剂，用于治疗黑色素瘤
DOI：
10.1002/ijc.32756
复制
发表时间：
2020-07
影响因子：
6.4
通讯作者：
Peng Cong
中科院分区：
文献类型：
--
作者：
Zhou Youyou;Huang Zunnan;Su Juan;Li Jie;Zhao Shuang;Wu Lisha;Zhang JiangLing;He Yijing;Zhang Guigui;Tao Juan;Zhou Ji;a;Chen Xiang;Peng Cong
The M2 splice isoform of pyruvate kinase (PKM2) is a key enzyme for generating pyruvate and ATP in the glycolytic pathway, whereas the role of PKM2 in tumorigenesis remains a subject of debate. In our study, we found PKM2 is highly expressed in melanoma patients and the malignance is positively correlated with high PKM2 activity and glycolytic capability in melanoma cells. Suppression of PKM2 expression by knocking down markedly attenuated malignant phenotype both in vitro and in vivo, and restoration of PKM2 expression in PKM2 depleted cells could rescue melanoma cells proliferation, invasion and metastasis. With the data indicating PKM2 as a potential therapeutic target, we performed screening for PKM2 inhibitors and identified benserazide (Ben), a drug currently in clinical use. We demonstrated that Ben directly binds to and blocks PKM2 enzyme activity, leading to inhibition of aerobic glycolysis concurrent up‐regulation of OXPHOS. Of note, despite PKM2 is very similar to PKM1, Ben does not affect PKM1 enzyme activity. We showed that Ben significantly inhibits cell proliferation, colony formation, invasion and migration in vitro and in vivo. The specificity of Ben was demonstrated by the findings that, suppression of PKM2 expression diminishes the efficacy of Ben in inhibition of melanoma cell growth; ectopic PKM2 expression in normal cells sensitizes cells to Ben treatment. Interestingly, PKM2 activity and aerobic glycolysis are upregulated in BRAFi‐resistant melanoma cells. As a result, BRAFi‐resistant cells exhibit heightened sensitivity to suppression of PKM2 expression or treatment with Ben both in vitro and in vivo.
登录
查看更多内容
靶向 CD147 的 siRNA 通过下调糖酵解抑制人恶性黑色素瘤细胞的增殖、侵袭和 VEGF 产生
影响因子：
9.7
作者：
Su, Juan;Chen, Xiang;Kanekura, Takuro
通讯作者：
Kanekura, Takuro
影响因子：
4.6
作者：
Li W;Liu J;Zhao Y
通讯作者：
Zhao Y
影响因子：
8.8
作者：
Wang L;Xiong H;Wu F;Zhang Y;Wang J;Zhao L;Guo X;Chang LJ;Zhang Y;You MJ;Koochekpour S;Saleem M;Huang H;Lu J;Deng Y
通讯作者：
Deng Y
影响因子：
--
作者：
He X;Du S;Lei T;Li X;Liu Y;Wang H;Tong R;Wang Y
通讯作者：
Wang Y
影响因子：
3.5
作者：
N. Dizdar;A. Granérus;U. Hannestad;A. Kullman;A. Ljungdahl;J. Olsson;B. Kågedal
通讯作者：
N. Dizdar;A. Granérus;U. Hannestad;A. Kullman;A. Ljungdahl;J. Olsson;B. Kågedal